Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
Authors
Keywords
-
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-12
DOI
10.1186/s12885-018-5021-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
- (2017) Maud Rijnders et al. EUROPEAN UROLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
- (2017) Jonathan M. Lehman et al. Current Oncology Reports
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
- (2017) Giulia Viale et al. Biomed Research International
- Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
- (2016) Piera Gargiulo et al. CANCER TREATMENT REVIEWS
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
- (2015) Y.J. Bang et al. EUROPEAN JOURNAL OF CANCER
- Intrahepatic Cholangiocarcinoma: Management Options and Emerging Therapies
- (2013) Rebecca M. Dodson et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Classification OMS 2010 des tumeurs digestives : la quatrième édition
- (2011) Jean-François Fléjou ANNALES DE PATHOLOGIE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More